Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis

Am J Hematol. 2021 Dec 1;96(12):E475-E478. doi: 10.1002/ajh.26373. Epub 2021 Oct 16.

Authors

Neta Schiller Salton¹, Moran Szwarcwort², Inna Tzoran^{1

3}, Netanel A Horowitz^{1

3}, Tsila Zuckerman^{1

3}, Nurit Horesh³, Yael Shachor-Meyouhas⁴, Khetam Hussein⁵, Noa Lavi^{1

3}

Affiliations

¹ The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
² Virology Laboratory, Rambam Health Care Campus, Haifa, Israel.
³ Department of Hematology, Rambam Health Care Campus, Haifa, Israel.
⁴ Pediatric Infectious Diseases Unit, Rambam Health Care Campus, Haifa, Israel.
⁵ Infectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Viral / immunology
BNT162 Vaccine / therapeutic use*
COVID-19 / complications
COVID-19 / immunology
COVID-19 / prevention & control*
Female
Humans
Immunity, Humoral*
Immunoglobulin G / immunology
Immunoglobulin Light-chain Amyloidosis / complications*
Immunoglobulin Light-chain Amyloidosis / immunology
Male
Multiple Myeloma / complications*
Multiple Myeloma / immunology
Prospective Studies

Substances

Antibodies, Viral
Immunoglobulin G
BNT162 Vaccine

Grants and funding

Promedico